OUR EXPERT NETWORK

• Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics

  RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.

• A New Purification Strategy For The Removal Of dsRNA Impurities From IVT mRNA Products

  NIST research introduces a gentle SEC method that separates dsRNA impurities from IVT mRNA by tweaking buffer pH, achieving 81.8% target recovery without transcript damage.

• The Second Holy Grail Of Gene Editing: Large Knock-Ins

  Exploring the race to achieve large gene knock-ins, emerging editing platforms, and how overcoming this challenge could unlock therapies for many inherited diseases.

• The Preclinical Gauntlet: Securing Capital And Designing Regulatory Pathways For Ultra-Rare ASO Drugs (Pt. 2)

  SynaptixBio CEO Dan Williams explains why funding, regulatory strategy, toxicology, and disciplined execution — not just science — determine success in advancing ultra-rare ASO therapies.

• Bridging The Atlantic: A European Executive's Guide To Building A Successful U.S. RNA Business (Pt. 2)

  European RNA biotech leaders can accelerate U.S. success by aligning fundraising, partnerships, manufacturing, hiring, and regulatory strategy from day one.